<SEC-DOCUMENT>0001193125-23-300043.txt : 20231220
<SEC-HEADER>0001193125-23-300043.hdr.sgml : 20231220
<ACCEPTANCE-DATETIME>20231220172427
ACCESSION NUMBER:		0001193125-23-300043
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20231220
DATE AS OF CHANGE:		20231220

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annexon, Inc.
		CENTRAL INDEX KEY:			0001528115
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				275414423
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-258863
		FILM NUMBER:		231502209

	BUSINESS ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(650)-822-5500

	MAIL ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annexon, Inc.
		CENTRAL INDEX KEY:			0001528115
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				275414423
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(650)-822-5500

	MAIL ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d672960dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Issuer Free Writing Prospectus </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 433 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Dated December&nbsp;20, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Relating to Prospectus Dated May&nbsp;3, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-258863</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ANNEXON, INC. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g672960g1218171659746.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to purchase Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This free writing prospectus relates only to the offering of shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase
common stock described below and should be read together with the prospectus dated May&nbsp;3, 2022 included in the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-258863),</FONT> as amended (the &#147;Prospectus&#148;), including the documents incorporated by reference therein. This free writing prospectus supplements the Prospectus primarily to reflect the terms
of certain <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and the shares of common stock issuable upon the exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, being offered by Annexon, Inc. (&#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; &#147;the Company&#148; and &#147;Annexon&#148;). Except as otherwise indicated, all information in this free writing prospectus and the Prospectus assumes no exercise of outstanding options or warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This free writing prospectus is qualified in its entirety by reference to the Prospectus, including the documents incorporated by reference therein. Financial
information and other information presented in the Prospectus or incorporated by reference therein is deemed to have changed to the extent affected by the changes described herein. This free writing prospectus should be read together with the
Prospectus, including the documents incorporated by reference therein, before making a decision in connection with an investment in the securities. Capitalized but not defined terms used in this free writing prospectus have the meanings given to
them in the Prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuer:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Annexon, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock offered by us:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">25,035,000 shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants offered by us:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We are also offering, in lieu of shares of our common stock to certain investors, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 18,379,861 shares of our common stock. The purchase price of each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant is equal to the price per share of our common stock at which the shares of our common stock are being sold in this offering, minus $0.001, the exercise price of each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable from the date of issuance until fully exercised, subject to an ownership limitation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Listing:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares of our common stock are listed on the Nasdaq Global Select Market (&#147;Nasdaq&#148;) under the symbol &#147;ANNX.&#148; We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq
or any other national securities exchange or nationally recognized trading system. Without an active market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> being offered in this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no public trading market for <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> being offered in this offering, and we do not
expect a market to develop. In addition, we do not intend to list <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> on the Nasdaq or any other national securities exchange or nationally recognized trading system. Without an
active trading market, the liquidity of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not
receive any meaningful amount of additional funds upon the exercise of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant has an exercise price of $0.001 per share of common stock.
<FONT STYLE="white-space:nowrap">Each&nbsp;pre-funded&nbsp;warrant</FONT> will be exercisable until it is fully exercised and by means of payment of the nominal cash purchase price upon exercise. Accordingly, we will not receive any meaningful
additional funds upon the exercise of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of <FONT
STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> will have no rights as common stockholders until such holders exercise <FONT STYLE="white-space:nowrap">their&nbsp;pre-funded&nbsp;warrants</FONT> and acquire shares of our common
stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until holders of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> exercise
<FONT STYLE="white-space:nowrap">their&nbsp;pre-funded&nbsp;warrants</FONT> and acquire shares of our common stock, such holders will have no rights with respect to the shares of our common stock underlying
<FONT STYLE="white-space:nowrap">such&nbsp;pre-funded&nbsp;warrants.</FONT> Upon exercise of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants,</FONT> the holders will be entitled to exercise the rights of a common stockholder only
as to matters for which the record date occurs after the exercise date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial holders of shares of our common stock may
not be permitted to exercise <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> that they hold. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of <FONT
STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants</FONT> will not be entitled to exercise any portion of <FONT STYLE="white-space:nowrap">any&nbsp;pre-funded&nbsp;warrant</FONT> that, upon giving effect to such exercise, would cause:
(i)&nbsp;the aggregate number of shares of our common stock beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the number of shares of our common stock immediately after giving effect to the exercise; or
(ii)&nbsp;the combined voting power of our securities beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of our securities outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of <FONT STYLE="white-space:nowrap">the&nbsp;pre-funded&nbsp;warrants.</FONT> As a result, you may not be able to exercise
<FONT STYLE="white-space:nowrap">your&nbsp;pre-funded&nbsp;warrants</FONT> for shares of our common stock at a time when it would be financially beneficial for you to do so. In such a circumstance, you could seek to sell <FONT
STYLE="white-space:nowrap">your&nbsp;pre-funded&nbsp;warrants</FONT> to realize value, but you may be unable to do so in the absence of an established trading market and due to applicable transfer restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us
from our issuance and sale of shares of our common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be approximately $117.1&nbsp;million, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. We will receive only nominal additional proceeds from any exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to advance the global
registrational program for ANX007 in geographic atrophy, the development of our pipeline of other product candidates and for working capital and other general corporate purposes. Based upon our current operating plan, we believe that the net
proceeds of our offering, together with our existing cash and cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2026. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of
the material attributes and characteristics of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. The form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be provided to the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant purchasers in this offering and will be filed as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the Securities and Exchange Commission
(&#147;SEC&#148;), in connection with this offering. The following summary is subject in all respects to the provisions contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant entitles the holder thereof to purchase
shares of our common stock at an exercise price equal to $0.001 per share. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable at any time beginning on the date of issuance. The number of shares of our common stock
issuable upon exercise of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is subject to adjustment upon certain corporate events, including certain stock dividends and splits, combinations, reclassifications and certain other events.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant
by delivering an exercise notice, completed and duly signed, and payment in cash of the exercise price for the number of shares of our common stock for which the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is being exercised. The
holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may also satisfy its obligation to pay the exercise price through a &#147;cashless exercise,&#148; in which the holder receives the net value of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant in shares of common stock determined according to the formula set forth in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a holder&#146;s exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, we will issue the shares of common stock to which the holder
is entitled pursuant to such exercise within two trading days after the exercise date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant will not be entitled to exercise any portion of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of our common stock beneficially owned by
such holder (together with its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder for purposes of Section&nbsp;13(d) of the Exchange Act) to exceed 9.99% of the total number of then issued
and outstanding shares of common stock, as such percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and subject to such holder&#146;s rights under the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant to increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61&nbsp;days&#146; prior notice from such holder to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the consummation of a fundamental transaction (as described in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants), the holders of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will be entitled to receive, upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the kind and amount of securities, cash, or other property that such holders would
have received had they exercised the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants immediately prior to such fundamental transaction, without regard to any limitations on exercise contained in the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable laws, a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may
be transferred at the option of the holder upon surrender of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to us together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if
applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no established public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and we do not expect a
market to develop. In addition, we do not intend to apply for listing of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any national securities exchange or other nationally recognized trading system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will initially serve as the warrant agent under the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants do not confer upon the holder any voting or other rights as our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional conforming changes are hereby made to
the Prospectus to reflect the changes described in this free writing prospectus. All terms of the Prospectus applicable to our common stock will be applicable to the shares underlying the <FONT STYLE="white-space:nowrap">pre-warrants</FONT> upon
issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed a registration statement, including the Prospectus, with the SEC for the offering to which this communication relates. Before you
invest, you should read the Prospectus and other documents we have filed with the SEC for more complete information about the Company and the offering. You may get these documents for free by visiting EDGAR on the SEC website at <I>www.sec.gov</I>.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g672960g1218171659746.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g672960g1218171659746.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, .,# 2(  A$! Q$!_\0
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MN?+M0D>!_$HX_45P?PCU3RM4O--<X%Q&)4!_O+U_0_I5'_A"O&__ #VD_P#
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MQ/VHOE?Z?UYG;?"7_D6[G_KX/\JX+QZQ3QU?,!DJZ$?A7>_"7_D6[G_KX/\
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M(\3:.FNZ!=6+ ;W7,9]&'(/YUX-)H.MJ?)?3;O*$C&PD ]\5](44JE%3=S3
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E/XU:^'^DWVEZ9>&\MVM4N+DR0VS')B7%==11?0+"T4E%(9__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
